Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Keeps “Buy” Rating at HC Wainwright

Eupraxia Pharmaceuticals (NASDAQ:EPRX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Thursday, MarketBeat Ratings reports. They currently have a $11.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 34.87% from the company’s previous close.

A number of other research firms have also recently commented on EPRX. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Friday, July 17th. Stifel Nicolaus set a $25.00 price target on Eupraxia Pharmaceuticals in a report on Thursday, September 24th. Wedbush started coverage on Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. They issued an “outperform” rating and a $17.00 price target on the stock. Wall Street Zen raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.80.

Eupraxia Pharmaceuticals Stock Down 10.4%

EPRX stock traded down $0.94 during mid-day trading on Thursday, reaching $8.16. The company had a trading volume of 147,260 shares, compared to its average volume of 316,450. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.00 and a quick ratio of 16.00. The stock has a 50 day simple moving average of $7.31 and a two-hundred day simple moving average of $7.02. The company has a market capitalization of $530.30 million, a price-to-earnings ratio of -8.00 and a beta of 1.07. Eupraxia Pharmaceuticals has a 52 week low of $5.25 and a 52 week high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. As a group, equities analysts predict that Eupraxia Pharmaceuticals will post -0.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Persistent Asset Partners Ltd acquired a new stake in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at $25,000. AXQ Capital LP raised its holdings in shares of Eupraxia Pharmaceuticals by 34.2% in the 2nd quarter. AXQ Capital LP now owns 21,150 shares of the company’s stock valued at $140,000 after purchasing an additional 5,390 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at $40,000. Bank of America Corp DE raised its holdings in shares of Eupraxia Pharmaceuticals by 5.9% in the 1st quarter. Bank of America Corp DE now owns 268,221 shares of the company’s stock valued at $1,942,000 after purchasing an additional 14,900 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of Eupraxia Pharmaceuticals by 33.2% in the 1st quarter. Royal Bank of Canada now owns 261,376 shares of the company’s stock valued at $1,893,000 after purchasing an additional 65,099 shares in the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc (NASDAQ:EPRX) is a clinical-stage biotechnology company based in Canada. The company develops locally administered therapies intended to treat inflammatory, fibrotic and other diseases while limiting patients’ exposure to medication throughout the body.

Eupraxia’s development programs are built around its proprietary Diffusion Driven Drug Delivery (3D) platform. The technology is designed to provide controlled, sustained release of pharmaceutical compounds at targeted sites, potentially extending treatment effects and reducing systemic side effects.

The company’s lead product candidate, EP-104I, is an extended-release formulation of fluticasone propionate being developed for intra-articular administration in patients with osteoarthritis of the knee.